Written description and enablement
Section 112(a) imposes two distinct disclosure requirements on every patent. The specification must contain a written description of the invention and must enable a person of ordinary skill to make and use the full scope of the claimed invention. The two requirements share a statutory home but operate independently. They are the principal levers by which courts police the boundary between the patentee's actual contribution and what the claims attempt to cover.
The rule
Under 35 U.S.C. § 112(a), the specification of every patent must contain "a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same." The Federal Circuit has long read this provision to impose two separate requirements: a written description requirement, satisfied when the specification reasonably conveys to a person of ordinary skill that the inventor possessed the claimed subject matter as of the filing date; and an enablement requirement, satisfied when a person of ordinary skill could make and use the full scope of the claimed invention without undue experimentation.
The two requirements may be violated independently. A specification can describe an invention that it does not enable; it can also enable making and using subject matter that it does not adequately describe.
Statutory and constitutional source
The Patent Act provides that the specification "shall contain a written description of the invention, and of the manner and process of making and using it." 35 U.S.C. § 112(a). The America Invents Act renumbered the paragraphs of § 112 (formerly § 112, ¶ 1) but did not change the substance of subsection (a). The constitutional anchor is again the Patent and Copyright Clause, U.S. Const. art. I, § 8, cl. 8, which the Supreme Court has interpreted to require that exclusive rights extend only to what the inventor has in fact contributed to the public domain through disclosure.
The framework the courts apply
Written description after Ariad
The Federal Circuit's en banc decision in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010), confirmed that § 112(a) imposes a written description requirement separate from enablement. The test is objective: the specification must "reasonably convey[] to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date." Ariad, 598 F.3d at 1351. Possession is shown by description in the specification, not by hindsight reconstruction.
For genus claims, particularly in unpredictable arts such as biotechnology and chemistry, mere disclosure of a function or a method of identification is generally insufficient. Ariad required either disclosure of a representative number of species falling within the genus or disclosure of structural features common to members of the genus that allow a skilled artisan to visualize or recognize the members of the genus. Ariad, 598 F.3d at 1350. The court in Ariad invalidated claims to methods of reducing NF-κB activity that recited the function of the desired molecule but disclosed no structural information about the molecules that could perform it.
Enablement and the Wands factors
The enablement requirement asks whether a person of ordinary skill could make and use the full scope of the claimed invention without undue experimentation. In re Wands, 858 F.2d 731 (Fed. Cir. 1988), set out factors that bear on the inquiry:
- The quantity of experimentation necessary;
- The amount of direction or guidance presented;
- The presence or absence of working examples;
- The nature of the invention;
- The state of the prior art;
- The relative skill of those in the art;
- The predictability or unpredictability of the art; and
- The breadth of the claims.
The factors are not weighed mechanically; they guide a fact-intensive judgment. Some experimentation is permitted; only undue experimentation precludes enablement.
Amgen v. Sanofi and genus claims
The Supreme Court in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), addressed enablement of broad genus claims for the first time in over a century. The patentee's claims covered all antibodies that bind to specified amino-acid residues on the PCSK9 protein and block PCSK9 from binding to LDL receptors. The specification disclosed the amino-acid sequences of 26 antibodies that performed the function and described "roadmap" and "conservative substitution" methods for obtaining additional antibodies meeting the functional criteria.
The Court unanimously affirmed invalidation for lack of enablement. Writing for the Court, Justice Gorsuch held that "if a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent's specification must enable a person skilled in the art to make and use the entire class." Amgen, 598 U.S. at 610. The Court rejected the argument that a specification meets § 112(a) if it teaches a person of ordinary skill how to find additional embodiments through routine experimentation, where the routine work amounted to a research program rather than a routine application of disclosed teachings.
Amgen reaffirmed the long-standing principle that the specification must enable the full scope of what is claimed, including the cases O'Reilly v. Morse, 56 U.S. (15 How.) 62 (1853), and The Incandescent Lamp Patent, 159 U.S. 465 (1895). The decision did not announce a new test, but it strongly reinforced the limits on functionally claimed genuses, particularly in unpredictable arts.
The possession test and functional claims
The written description "possession" test scrutinizes claims that recite a desired function or result. A claim that captures all things that perform a function — without disclosing what those things are or sufficient structural features common to the genus — typically fails written description, fails enablement, or both. The Federal Circuit's decisions in Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997), AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., 759 F.3d 1285 (Fed. Cir. 2014), and Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., 941 F.3d 1149 (Fed. Cir. 2019), illustrate the principle in different settings.
Functional claiming is not categorically prohibited, but it places significant disclosure demands on the specification. Where a claim term is purely functional and lacks corresponding structural disclosure, the patentee may also face definiteness issues under § 112(b) and means-plus-function treatment under § 112(f).
Burden and proof
Issued patents are presumed valid under 35 U.S.C. § 282(a). An accused infringer must prove invalidity for failure of written description or enablement in district court by clear and convincing evidence. Microsoft Corp. v. i4i Limited Partnership, 564 U.S. 91 (2011). In post-grant review, the standard is preponderance of the evidence under 35 U.S.C. § 326(e); these grounds may be raised in PGR but not in inter partes review, which is limited to § 102 and § 103 grounds based on patents and printed publications.
Both written description and enablement are questions of law, with underlying questions of fact. Ariad, 598 F.3d at 1351; Wands, 858 F.2d at 737. Compliance with the requirements is determined as of the effective filing date of the claim.
Interaction with related doctrines
Written description and enablement frequently interact with claim construction: the broader the construction, the harder it is to satisfy disclosure obligations across the full claim scope. They also interact with anticipation through the priority-date analysis: a continuation application receives the priority date of its parent only if the parent provides § 112(a) support for the claims as later issued.
Written description and enablement bear directly on the use of doctrine of equivalents arguments. Equivalents must still find support in the specification; a patentee cannot recapture through equivalents what was not adequately disclosed. The doctrines also relate to definiteness under § 112(b) and to means-plus-function claiming under § 112(f), which the Federal Circuit has tightened in Williamson v. Citrix Online, LLC, 792 F.3d 1339 (Fed. Cir. 2015) (en banc).
Practical notes
Disclosure-based invalidity defenses are most powerful in the life sciences and chemistry, where genus claims with limited working examples are common and the predictability of the art is contested. Defendants in Delaware and Eastern District of Texas Hatch-Waxman litigation routinely combine written description and enablement attacks against pharmaceutical patents covering broad antibody or small-molecule genuses.
Written description challenges are especially relevant when claims have been amended during prosecution to capture an accused product. The accused infringer asks whether the amended claim is supported by the original specification; if not, the claim is invalid for lack of written description, and any priority claim falls. New-matter rejections during prosecution are the prosecution-side counterpart of this litigation defense.
The PTAB applies the same § 112(a) standards in PGR and reissue, with preponderance burdens and broader prior-art universes. Patentees defending PTAB challenges often rely on expert testimony establishing that representative examples and disclosed structural features support the claimed genus.
Open questions
The boundary between routine experimentation and undue experimentation, especially for biological genus claims, is contested after Amgen v. Sanofi. The decision affirmed long-standing doctrine but left unanswered how many embodiments and how much guidance suffice in particular technologies. Lower courts and the PTAB are working through the implications for antibody, peptide, and small-molecule genus claims, and the Federal Circuit's emerging case law is inconsistent across panels.
The relationship between written description and enablement for genus claims is also unsettled. Some Federal Circuit opinions treat them as substantially overlapping; others insist on separate analyses. Whether Amgen implicitly tightens the written description analysis as well as enablement remains an open question that will be litigated for years.
See also
- Definiteness under § 112(b)The companion § 112 requirement focused on claim clarity.
- Anticipation under § 102Priority disputes turn on whether the earlier filing satisfies § 112(a).
- Obviousness under § 103Companion validity ground often litigated alongside § 112.
- Claim constructionDefines the scope that the specification must support.
- Doctrine of equivalentsEquivalents are constrained by what the specification supports.
- Post-grant reviewThe PTAB forum where § 112 grounds may be raised.
- Alice v. CLS BankFunctional claims raise both eligibility and disclosure concerns.
Last reviewed: 2026